ARTICLE | Clinical News
Crofelemer: Additional Phase III data
March 19, 2012 7:00 AM UTC
In November, Napo terminated a 2008 deal that gave Salix rights to crofelemer in North America, Japan and Europe, excluding Liechtenstein, Norway and Switzerland. At the time, Napo claimed Salix breac...